Producer
Par Sterile Products (Endo International / Par Pharmaceutical)
Par Sterile Products LLC (Woodcliff Lake NJ; subsidiary of Par Pharmaceutical Holdings, itself subsidiary of Endo International; Par acquired by Endo 2015 for $8.05B) is a significant US generic injectable pharmaceutical manufacturer producing morphine sulfate injection, fentanyl citrate injection, and hydromorphone HCl injection for hospital use. Par Pharmaceutical was a major injectable generics manufacturer serving hospital group purchasing organizations (GPOs). Endo International filed for Chapter 11 bankruptcy in August 2022 (opioid litigation liability) and emerged from bankruptcy in 2024 — creating supply chain uncertainty for hospitals dependent on Par Sterile injectable opioids during the bankruptcy period. The Endo/Par situation illustrates the financial fragility of injectable generic pharmaceutical manufacturers who face simultaneous opioid litigation liability and thin margin economics.
1
Inputs supplied
1
Goods downstream
1
Facilities
0
Stories
What they make
1 input Par Sterile Products (Endo International / Par Pharmaceutical) supplies
Click an input to see every good that depends on it, every country that produces it, and every other company in the supply chain.
Where it shows up
Goods downstream
Essential goods that depend on something Par Sterile Products (Endo International / Par Pharmaceutical) makes — pick one to see the full supply chain.
What else they do
Business segments
The company's full revenue map — where this supply-chain role fits within their broader business.
Generic Controlled Injectable Opioids
55%Hospital Sterile Non-Opioid Injectables
30%Specialty Generics
15%
Intelligence
What's known
Sourced claims about this company's role in supply chains — chokepoints, concentration, incidents, dual-use connections.
Did you know2022
Par Sterile Products operated through Endo International's 2022-2024 Chapter 11 bankruptcy without supply disruption — an unusual situation where a bankrupt company was explicitly protected by courts because the drug supply chain could not afford its failure. The opioid epidemic legal liability supply chain (bankrupting Endo through litigation settlements) and the hospital critical care pharmaceutical supply chain (depending on Par Sterile for morphine, hydromorphone, fentanyl injectables) converged at the same corporate entity, requiring courts to balance creditor recovery against maintaining the generic injectable drug supply for hospitals. The opioid crisis simultaneously drove the company bankrupt AND required the company to keep producing opioids — from the same manufacturing sites.
ASHP ↗Incident2022
Endo International PLC — parent company of Par Sterile Products, a significant US injectable opioid manufacturer — filed for Chapter 11 bankruptcy protection in August 2022 under the weight of opioid litigation liability estimated at over $8 billion. The bankruptcy was the largest pharmaceutical Chapter 11 to that date driven by opioid litigation. Endo had acquired Par Pharmaceutical Holdings in 2015 for $8.05 billion specifically to build a generic injectable pharmaceutical business; Par Sterile Products was a significant source of injectable opioid generics for US hospital formularies. During the Endo bankruptcy proceedings (August 2022-May 2024), hospital procurement teams faced uncertainty about Par Sterile's continued operations: would Par's manufacturing licenses transfer to a bankruptcy buyer? Would DEA quota authorizations lapse? Would FDA GMP commitments be maintained? The Endo/Par case illustrated that US injectable opioid supply reliability depends not just on manufacturing quality but on the financial solvency of the companies that hold the DEA Schedule II manufacturing registrations — registrations that cannot be rapidly transferred to new owners without DEA and FDA approval processes taking months to years.
Reuters ↗Origin2024
Par Pharmaceutical was founded in the 1970s as an independent generic pharmaceutical company and grew into one of the US's major generic drug manufacturers. Endo International (a specialty pharmaceutical company incorporated in Ireland for tax purposes, despite being operationally US-based) acquired Par Pharmaceutical in 2015 for $8.05 billion. Endo International filed for Chapter 11 bankruptcy in August 2022 after accumulating $8+ billion in opioid-related liabilities — one of the largest pharma bankruptcies in history. Par Sterile's generic injectable manufacturing continued operating through the bankruptcy under court protection because hospitals depended on its opioid and sterile injectable supply.
Endo International ↗